The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits

This Medical News article discusses the latest research about the use of nirmatrelvir-ritonavir, sold as Paxlovid, to treat COVID-19 and, possibly, to prevent or treat long COVID.

Authors

Publication Details

Journal
JAMA
Published
2024-09-06
DOI
https://doi.org/10.1001/jama.2024.16432
Citations
7
Primary Topic
COVID-19 Clinical Research Studies
Type
article
Field-Weighted Citation Impact
2.72
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits

Rita Rubin
7 citations
JAMA
COVID-19 Clinical Research Studies
2.72
article

The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits

Rita Rubin
article en
7 citations

Abstract

This Medical News article discusses the latest research about the use of nirmatrelvir-ritonavir, sold as Paxlovid, to treat COVID-19 and, possibly, to prevent or treat long COVID.

JAMAVol. 332(13)
Openalex Percentile: Top 9%
COVID-19 Clinical Research Studies
2.72
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits — Rita Rubin · JAMA (2024) | TGRS Research Map | TGRS